Early clinical studies to explore candidate biomarkers in targeted cancer therapies
PhD ceremony: Ms. C.N.A.M. Oldenhuis, 12.45 uur, Academiegebouw, Broerstraat 5, Groningen
Dissertation: Early clinical studies to explore candidate biomarkers in targeted cancer therapies
Promotor(s): prof. J.A. Gietema, prof. E.G.E. de Vries, prof. S. de Jong
Faculty: Medical Sciences
Currently, much information is becoming available from tumor cell biology research, opening opportunities for the development of specifically tumor targeting agents. In this thesis we studied the safety, tolerability and pharmacokinetics of two novel targeted agents in phase 1 studies. An oral angiogenesis inhibitor and the apoptosis inducing agonistic antibody mapatumumab both appeared safe in combination with chemotherapy. No pharmacokinetic interactions were seen. Further studies on this combination are therefore warranted.
| Last modified: | 13 March 2020 01.02 a.m. |
More news
-
29 November 2023
UMCG opent nieuwe faciliteit voor microbioomonderzoek 
Vandaag opent het UMCG de Groningen Microbioom Hub: een nieuwe faciliteit met state-of-the-art technologie waarin alle UMCG-expertise op het gebied van microbioomonderzoek samenkomt. Dit zorgt voor unieke mogelijkheden in onderzoek en maakt nieuwe...
-
28 November 2023
Science: more exciting than showbiz
Science often seems very complicated. Most people probably don't really know what researchers do, and what it takes to make a breakthrough. That is why it is important to keep the general public informed of what is happening in science, says Iris...
-
13 November 2023
UMCG beantwoordt vragen patiënten met hulp van AI
Het UMCG zet kunstmatige intelligentie (artificial intelligence, afgekort AI) in om zorgverleners te helpen bij het beantwoorden van schriftelijke vragen van patiënten. Dit gebeurt in samenwerking met andere ziekenhuizen vanuit de EPIC Nederlandse...